Cure My Disease

Don't miss your cure!

 Log in / Sign up

A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma

NCT ID NCT07721376

Ongoing Disease control Sponsor: Maimónides Biomedical Research Institute of Córdoba Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether a six-month course of dupilumab can calm the immune system enough for patients with severe olive pollen asthma to then benefit from standard allergy immunotherapy. Researchers will use advanced molecular profiling to understand how the treatment restores immune balance. The goal is to find a way to reduce dependence on expensive biologic drugs and improve long-term asthma control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a biologic drug called dupilumab followed by allergen immunotherapy
What this could lead to
If successful, this approach could allow patients with severe olive pollen asthma to switch from costly biologic therapy to long-term immunotherapy, potentially altering the disease course.
What could go wrong
This is a very small early-stage study with only 18 participants. The strategy may not work for all patients, and biologic therapy carries risks like injection reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGY AND ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic asthma allergic disease asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLERGY AND ASTHMA POLLEN; ALLERGY, ASTHMA SEVERE ASTHMA

Contacts and locations

Locations

  • Hospital Universitario Reina Sofia

    Córdoba, Cordoba, 14004, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.